Kjell-Morten Myhr

Author information from the last article

E-post: kjell-morten.myhr@helse-bergen.no

Kjell-Morten Myhr er professor i Nevrologi ved Universitetet i Bergen og overlege ved Nevrologisk avdeling, Haukeland universitetssjukehus. Han er senterleder for NorTrials hjernehelse og nestleder for Neuro-SysMed (forskningssenter for klinisk behandling). Han er medlem i Sykehusinnkjøps MS-spesialistgruppe og faglig leder i arbeidsgruppen knyttet til nasjonal faglig retningslinje for diagnostikk og behandling av multippel sklerose i regi av Helsedirektoratet.

Articles by Kjell-Morten Myhr

NorTrials drives growth in Norwegian clinical trials

Peder Langeland Myhre,
Åslaug Helland,
Kjell-Morten Myhr,
Jan Gunnar Skogås,
Thomas Langø,
Rasmus Goll,
Jens Vikse,
Signe Øien Fretland

08.01.2026: NorTrials has helped increase the focus on clinical trials in Norway. NorTrials was established by Erna Solberg's government in 2022 as one of the initiatives in the National Action Plan for Clinical Trials. The initiative is a partnership between the specialist health service and the pharmaceutical...

New centres to carry out more clinical trials in Norway

Inger Marie Skoie,
Jan Gunnar Skogås,
Thomas Langø,
Kjell-Morten Myhr,
Peder Langeland Myhre,
Rasmus Goll,
Signe Øien Fretland,
Åslaug Helland

20.01.2023: Six NorTrials centres for clinical research have been established at the university hospitals. Their objective is to increase the number of clinical trials and improve patient treatment. We know that patients treated in institutions where clinical trials are undertaken have better outcomes (1). This...

Breastfeeding and treatment for multiple sclerosis

Øivind Torkildsen,
Brit Ellen Rød,
Lars Bø,
Stig Wergeland,
Trygve Holmøy,
Kjell-Morten Myhr

24.10.2022: Monoclonal antibody therapy is effective for multiple sclerosis, and only small amounts of antibodies are transferred to breast milk. Even though the approved product descriptions advise against breastfeeding during medicinal treatment, several of the most effective MS drugs are compatible with...

Disease-modifying therapy for multiple sclerosis

Trygve Holmøy,
Gro Owren Nygaard,
Kjell-Morten Myhr,
Lars Bø

10.05.2021: High-efficacy therapy from the time of diagnosis substantially improves the prognosis for multiple sclerosis. The national guidelines on MS nevertheless recommend less effective therapy for many patients, and must be updated in pace with medical advances. We consider in the following how multiple...

Progressive multifocal leukoencephalopathy

Karl Bjørnar Alstadhaug,
Kjell-Morten Myhr,
Christine Hanssen Rinaldo

12.12.2017: Progressive multifocal leukoencephalopathy is a rare, opportunistic infection of the central nervous system caused by the John Cunningham virus (JCV). There is no effective antiviral treatment available, and restoring immunocompetence is essential for survival. If this occurs too quickly, however...